Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30127361 | 0.90 | MEN1 (0.48) | GRM5MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL23973316 | 0.83 | HSD11B1 (0.44) | MEN1KMT2ASMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL16337747 | 0.82 | MEN1 (0.48) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL23973341 | 0.81 | FKBP1A (0.48) | MEN1KMT2ASMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL4012501 | 0.81 | P2RX7 (0.38) | MEN1KMT2ARAB9ANR1H2NR1H3 | |
| SCHEMBL22120717 | 0.81 | MEN1 (0.46) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL14142233 | 0.80 | P2RX7 (0.37) | GRM5 | |
| SCHEMBL2359115 | 0.80 | SMN1; SMN2 (0.44) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL22657130 | 0.80 | P2RX7 (0.43) | GRM5MEN1KMT2ACYP2C19L3MBTL1 | |
| SCHEMBL23973195 | 0.79 | FAAH (0.44) | GRM5MEN1KMT2AGAAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4200297-B1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688789-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1730114-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | disclosed |
| WO-2006061126-A2 | DIBENZOXAZEPINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006061126-A2 | DIBENZOXAZEPINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| WO-2005087746-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | GRM5 1577/4885MEN1 2828/4885KMT2A 2169/4885 |
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | PSMB2, PSMB7, MDM2 | GRM5 3206/4885MEN1 4386/4885KMT2A 1526/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | GRM5 3833/4885MEN1 1552/4885KMT2A 1091/4885 |
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR3 | GRM5 2704/4885MEN1 4814/4885KMT2A 2237/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | GRM5 1577/4885MEN1 2828/4885KMT2A 2169/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | GRM5 1310/4885MEN1 3823/4885KMT2A 1792/4885 |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | HTR6, BDKRB1, HTR7 | GRM5 318/4885MEN1 1588/4885KMT2A 1848/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | GRM5 2904/4885MEN1 1955/4885KMT2A 767/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | GRM5 4318/4885MEN1 1033/4885KMT2A 2057/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | GRM5 3152/4885MEN1 4330/4885KMT2A 2021/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | GRM5 2523/4885MEN1 1978/4885KMT2A 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.